Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Food advertisements, Tech advertisements.
- Who it may be relevant to
- Registry conditions: GLP - 1. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring the Influence of GLP-1 Medications on External Food Cue Reactivity and Resultant Food Choice and Intake
Overview
The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption? Participants will: * report daily food consumption for a total of 10 days, * receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days, * answer several questionnaires, * and complete two in-person visits to complete a virtual reality food selection task.
Interventions
- Behavioral Food advertisements
Videos and images of food and beverage advertisements from popular brands and/or restaurants - Behavioral Tech advertisements
Video and photo advertisements of popular tech tools
Primary outcome measures
- Mean food cue reactivity scores in the afternoon [Time frame: 7-day period of all afternoon survey responses]
- Mean food cue reactivity scores in the morning [Time frame: 7-day period of all morning survey responses]
- Mean food cue reactivity scores in the evening [Time frame: 7-day period of all evening survey responses]
- Mean food cue reactivity scores overall [Time frame: 7-day period of all survey responses]
- Energy density of consumed foods [Time frame: 7 days]
Secondary outcome measures (5)
- Change from baseline in energy density of foods selected in the virtual buffet [Time frame: Baseline and 7 days]
- Changes in food noise since being on medication questionnaire [Time frame: Baseline]
- Changes in reasons for purchasing foods questionnaire [Time frame: Baseline]
- Individual Food Cue Responsiveness--Trait [Time frame: Baseline]
- Change in brand familiarity, liking, and/or craving [Time frame: Baseline and 7 days]
Eligibility criteria
Inclusion criteria
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
- Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
- Fluent in English
Exclusion criteria
- Do not have consistent access to a smart phone that can access the study software
- Diagnosed with cognitive or physical disability or epilepsy
- Adults taking a compound GLP-1
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07505134 · STUDY00028881